GNA12, G protein subunit alpha 12, 2768

N. diseases: 130; N. variants: 16
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASCAT Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. 28067908 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASCAT Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. 26974007 2016
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASCAT Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. 26192919 2015
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASCAT Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. 23128233 2012
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASDB Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. 23128233 2012
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASCAT Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. 21297633 2011
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 Biomarker disease BEFREE Genetic evidence has also demonstrated the importance of barrier function to the development of ulcerative colitis (HNF4A, LAMB1, CDH1 and GNA12). 21300624 2011
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 GeneticVariation disease GWASDB Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. 21297633 2011
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.410 Biomarker disease CTD_human Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. 21297633 2011
CUI: C0033975
Disease: Psychotic Disorders
Psychotic Disorders
0.300 Biomarker group PSYGENET Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis. 25266742 2014
CUI: C0349204
Disease: Nonorganic psychosis
Nonorganic psychosis
0.300 Biomarker disease PSYGENET Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis. 25266742 2014
CUI: C0151744
Disease: Myocardial Ischemia
Myocardial Ischemia
0.300 Biomarker disease CTD_human Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study. 16214533 2005
CUI: C0005890
Disease: Body Height
Body Height
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0005890
Disease: Body Height
Body Height
0.100 GeneticVariation phenotype GWASCAT Genetic analyses of diverse populations improves discovery for complex traits. 31217584 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Gastroenteropancreatic neuroendocrine tumours (GEP NET) are a heterogeneous group of rare tumours that have distinct effects on the body due to their tumour location and potential to secrete hormones and peptides. 31550712 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE GEP-NET primary tumor location or secretory syndrome did not influence the risk for MetS. 31533348 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Immunotherapy might be a promising therapeutic approach in GEP-NENs especially in tumors with high TILs. 30608901 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE The results included the identification of 70% of SLN-negative patients who experienced metastasis as Class 2, the discovery of reduced recurrence-free survival for patients with thin tumors and Class 2B biology compared with that of those with Class 1A biology (P < .0001); and determination of the 31-GEP test as an independent predictor of risk compared with traditional staging factors in patients with stage I to IIA tumors. 30081113 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Effect of RMP on tumor progression in nude mouse models was assessed by measurement of volume and weight of tumors. 31333787 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Herein, we studied whether primary tumor site affects survival in patients with GEP-NETs and liver metastases (NELM). 30992703 2019
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors
0.100 GeneticVariation group BEFREE We analyzed the relationship between metabolic syndrome and histological, epidemiological, and prognosis variables in two cohorts of patients with neuroendocrine tumors (NETs): those with lung carcinoids (LCs; n = 81) and those with gastroenteropancreatic NET (GEP-NET; n = 100). 30265346 2019
CUI: C0206754
Disease: Neuroendocrine Tumors
Neuroendocrine Tumors
0.100 Biomarker group BEFREE An association of well-differentiated gastroenteropancreatic neuroendocrine tumours (WD GEP NETs) with metabolic syndrome (MetS) was recently described. 31466863 2019
CUI: C0424621
Disease: Body Fat Distribution
Body Fat Distribution
0.100 GeneticVariation phenotype GWASCAT Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects. 30664634 2019
CUI: C0424678
Disease: Lean body mass
Lean body mass
0.100 GeneticVariation phenotype GWASCAT Genomics of body fat percentage may contribute to sex bias in anorexia nervosa. 30593698 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE RMP might play an important role in defects of apoptosis, hence the chemotherapeutic resistance in hepatocellular carcinoma. 31754340 2019